ccmk
2021-10-06
Wows..
Ocugen Stock Up on Development Pact for Covid Vaccine Candidate<blockquote>Ocugen储备了新冠候选疫苗的开发协议</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":829943411,"tweetId":"829943411","gmtCreate":1633466512192,"gmtModify":1633466512500,"author":{"id":3575640395742421,"idStr":"3575640395742421","authorId":3575640395742421,"authorIdStr":"3575640395742421","name":"ccmk","avatar":"https://static.tigerbbs.com/a90d67ad1fb38a136eae07512ce11d0f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":15,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wows.. </p></body></html>","htmlText":"<html><head></head><body><p>Wows.. </p></body></html>","text":"Wows..","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/829943411","repostId":1173343014,"repostType":4,"repost":{"id":"1173343014","kind":"news","pubTimestamp":1633444442,"share":"https://www.laohu8.com/m/news/1173343014?lang=zh_CN&edition=full","pubTime":"2021-10-05 22:34","market":"us","language":"en","title":"Ocugen Stock Up on Development Pact for Covid Vaccine Candidate<blockquote>Ocugen储备了新冠候选疫苗的开发协议</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1173343014","media":"Thestreet","summary":"Shares of Ocugen (OCGN) jumped after the drugmaker said it entered a development-and-supply agreemen","content":"<p>Shares of Ocugen (<b>OCGN</b>) jumped after the drugmaker said it entered a development-and-supply agreement with Bharat Biotech tied to Ocugen's Covid-19 vaccine candidate.</p><p><blockquote>Ocugen股份（<b>OCGN</b>）在该制药商表示与Bharat Biotech签订了与Ocugen的Covid-19候选疫苗相关的开发和供应协议后，股价上涨。</blockquote></p><p> In a Securities and Exchange Commission 8K filing, Ocugen said Bharat will supply it with clinical-trial materials and, if the drug is cleared by regulators, commercial supplies of finished drug product and drug components.</p><p><blockquote>Ocugen在向美国证券交易委员会提交的8K文件中表示，Bharat将向其提供临床试验材料，如果该药物获得监管机构批准，还将提供成品药品和药物成分的商业供应。</blockquote></p><p> Shares of Ocugen, Malvern, Pa., at last check were 7% higher at $7.22. Bharat is the Hyderabad, India, biotechnology company.</p><p><blockquote>宾夕法尼亚州马尔文市Ocugen的股价最近一次上涨7%，至7.22美元。Bharat是印度海得拉巴的生物技术公司。</blockquote></p><p> Ocugen also said in the SEC filing that it entered an amended accord with development partner CanSino Biologics. The agreement is tied to Ocugen's gene-therapy candidate, OCU410, to treat dry age-related macular degeneration.</p><p><blockquote>Ocugen还在提交给SEC的文件中表示，它与开发合作伙伴康希诺生物达成了一项修订后的协议。该协议与Ocugen的候选基因疗法OCU410相关，用于治疗干性年龄相关性黄斑变性。</blockquote></p><p> Under the amended accord, the companies will collaborate to develop OCU410. CanSino, the Tianjin, China, vaccine producer, will be responsible for the chemistry, manufacturing and controls of the clinical supplies.</p><p><blockquote>根据修订后的协议，两家公司将合作开发OCU410。中国天津的疫苗生产商康希诺将负责临床用品的化学、制造和控制。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Stock Up on Development Pact for Covid Vaccine Candidate<blockquote>Ocugen储备了新冠候选疫苗的开发协议</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Stock Up on Development Pact for Covid Vaccine Candidate<blockquote>Ocugen储备了新冠候选疫苗的开发协议</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Thestreet</strong><span class=\"h-time small\">2021-10-05 22:34</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Shares of Ocugen (<b>OCGN</b>) jumped after the drugmaker said it entered a development-and-supply agreement with Bharat Biotech tied to Ocugen's Covid-19 vaccine candidate.</p><p><blockquote>Ocugen股份（<b>OCGN</b>）在该制药商表示与Bharat Biotech签订了与Ocugen的Covid-19候选疫苗相关的开发和供应协议后，股价上涨。</blockquote></p><p> In a Securities and Exchange Commission 8K filing, Ocugen said Bharat will supply it with clinical-trial materials and, if the drug is cleared by regulators, commercial supplies of finished drug product and drug components.</p><p><blockquote>Ocugen在向美国证券交易委员会提交的8K文件中表示，Bharat将向其提供临床试验材料，如果该药物获得监管机构批准，还将提供成品药品和药物成分的商业供应。</blockquote></p><p> Shares of Ocugen, Malvern, Pa., at last check were 7% higher at $7.22. Bharat is the Hyderabad, India, biotechnology company.</p><p><blockquote>宾夕法尼亚州马尔文市Ocugen的股价最近一次上涨7%，至7.22美元。Bharat是印度海得拉巴的生物技术公司。</blockquote></p><p> Ocugen also said in the SEC filing that it entered an amended accord with development partner CanSino Biologics. The agreement is tied to Ocugen's gene-therapy candidate, OCU410, to treat dry age-related macular degeneration.</p><p><blockquote>Ocugen还在提交给SEC的文件中表示，它与开发合作伙伴康希诺生物达成了一项修订后的协议。该协议与Ocugen的候选基因疗法OCU410相关，用于治疗干性年龄相关性黄斑变性。</blockquote></p><p> Under the amended accord, the companies will collaborate to develop OCU410. CanSino, the Tianjin, China, vaccine producer, will be responsible for the chemistry, manufacturing and controls of the clinical supplies.</p><p><blockquote>根据修订后的协议，两家公司将合作开发OCU410。中国天津的疫苗生产商康希诺将负责临床用品的化学、制造和控制。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/ocugen-jumps-covid-vaccine-development-deal\">Thestreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"https://www.thestreet.com/investing/ocugen-jumps-covid-vaccine-development-deal","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173343014","content_text":"Shares of Ocugen (OCGN) jumped after the drugmaker said it entered a development-and-supply agreement with Bharat Biotech tied to Ocugen's Covid-19 vaccine candidate.\nIn a Securities and Exchange Commission 8K filing, Ocugen said Bharat will supply it with clinical-trial materials and, if the drug is cleared by regulators, commercial supplies of finished drug product and drug components.\nShares of Ocugen, Malvern, Pa., at last check were 7% higher at $7.22. Bharat is the Hyderabad, India, biotechnology company.\nOcugen also said in the SEC filing that it entered an amended accord with development partner CanSino Biologics. The agreement is tied to Ocugen's gene-therapy candidate, OCU410, to treat dry age-related macular degeneration.\nUnder the amended accord, the companies will collaborate to develop OCU410. CanSino, the Tianjin, China, vaccine producer, will be responsible for the chemistry, manufacturing and controls of the clinical supplies.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":448,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/829943411"}
精彩评论